Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

Annals of Oncology

Volumn 26, Issue 2, 2015, Pages 415-421

  Menzies, Alexander M ^a   Ashworth, M T ^b   Swann, S ^c   Kefford, R F ^a   Flaherty, K ^d   Weber, J ^e   Infante, J R ^f   Kim, K B ^g   Gonzalez, R ^h   Hamid, O ⁱ   Schuchter, L ^j   Cebon, J ^k   Sosman, J A ^l   Little, S ^c   Sun, P ^c   Aktan, G ^c   Ouellet, D ^c   Jin, F ^c   Long, G V ^a   Daud, A ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLAXOSMITHKLINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f SARAH CANNON RESEARCH INSTITUTE   (United States)

^g CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^h UNIVERSITY OF COLORADO CANCER CENTER   (United States)

ⁱ Angeles Clinic and Research Institute   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^l VANDERBILT UNIVERSITY   (United States)

more..

Author keywords

BRAF; Dabrafenib; Fever; Melanoma; Pyrexia; Trametinib

Indexed keywords

B RAF KINASE; CORTICOSTEROID; DABRAFENIB; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TRAMETINIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILL; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DISEASE ASSESSMENT; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; FLU LIKE SYNDROME; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MELANOMA; NIGHT SWEAT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RETREATMENT; RETROSPECTIVE STUDY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME TO TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; TREND STUDY; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; FEMALE; GENETICS; MALE; MIDDLE AGED; MUTATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FEVER; HUMANS; IMIDAZOLES; MALE; MELANOMA; MIDDLE AGED; MUTATION; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES;

EID: 84923927971     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu529     Document Type: Article

References (20)

1. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
2. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
3. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
4. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
5. Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-1888.
6. Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2014 Nov 16 [epub ahead of print].
7. Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893-1901.
8. Ascierto PA, Minor D, Ribas A et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013; 31: 3205-3211.
9. Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 1087-1095.
10. Daud A, Weber J, Sosman J et al. Overall survival (OS) update for BRF113220 Part C, a phase II three-arm randomized study of dabrafenib (D) alone vs combination of dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). Paper Presented at: Society for Melanoma Research International Congress, Philadelphia, PA, 2013.
11. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
12. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
13. Sosman JA, Daud A, Weber JS et al. BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients ( pts) with BRAF mutation-positive metastatic melanoma (MM). J Clin Oncol 2013; 31: abstract 9005.
14. Heidorn SJ, Milagre C, Whittaker S et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-221.
15. Poulikakos PI, Zhang C, Bollag G et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464: 427-430.
16. Infante JR, Fecher LA, Falchook GS et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 773-781.
17. Ribas A, Gonzalez R, Pavlick A et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF-mutated melanoma: a phase 1b study. Lancet Oncol 2014; 15: 954-965.
18. Dummer R, Robert C, Nyakas M et al. Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma. J Clin Oncol 2013; 31: abstract 9028.
19. Ouellet D, Gibiansky E, Leonowens C et al. Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites. J Clin Pharmacol 2014; 54: 696-706.
20. Lee CI, Menzies AM, Haydu LE et al. Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Melanoma Res 2014; 24: 468-474.